Rosiglitazone reverses tenofovir-induced nephrotoxicity

Kidney International

Volumn 74, Issue 7, 2008, Pages 910-918

  Libório, Alexandre B ^a   Andrade, Lúcia ^a   Pereira, Leonardo V B ^a   Sanches, Talita R C ^a   Shimizu, Maria H ^a   Seguro, Antonio C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute; Adenine tenofovir; Kidney failure; Reverse transcriptase inhibitors; Thiazolidinediones rosiglitazone; Vasodilator agents

Indexed keywords

AQUAPORIN 2; CARRIER PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ROSIGLITAZONE; SODIUM PHOSPHATE COTRANSPORTER; SODIUM PROTON EXCHANGE PROTEIN; TENOFOVIR DISOPROXIL;

ACIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MEGADOSE; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; GLUCOSURIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY PROXIMAL TUBULE; LOW DRUG DOSE; MALE; NEPHROTOXICITY; NONHUMAN; PHOSPHATURIA; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; TREATMENT DURATION; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; VASOCONSTRICTION;

ADENINE; ANIMALS; DRUG TOXICITY; GLOMERULAR FILTRATION RATE; HYPOGLYCEMIC AGENTS; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIA, FAMILIAL; KIDNEY DISEASES; MALE; MEMBRANE TRANSPORT PROTEINS; PHOSPHONIC ACIDS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLIDINEDIONES;

EID: 51849104174     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.252     Document Type: Article

References (43)

1. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate. Clin Ther 2002; 24: 1515-1548.
2. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612.
3. Birkus G, Hitchcock M, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723.
4. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, May 04, 2006. (Accessed September 23, 2006, at http://AIDSinfo.nih.gov.).
5. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
6. Breton G, Alexandre M, Duval X et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 2003; 36: 527-528.
7. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-1073.
8. Badiou S, De Boever CM, Terrier N et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006; 52: 335-338.
9. Antoniou T, Raboud J, Chirhin S et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6: 284-290.
10. El Sahly HM, Teeter L, Zerai T et al. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS 2006; 20: 786-787.
11. Earle KE, Seneviratne T, Shaker J et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004; 19: 714-721.
12. Izzedine H, Isnard-Bagnis C, Hulot JS et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 1074-1076.
13. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-1333.
14. Rollot F, Nazal EM, Chauvelot-Moachon L et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37: E174-E176.
15. Parsonage MJ, Wilkins EG, Snowden N et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341-346.
16. Van Rompay KK, Brignolo LL, Meyer DJ et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48: 1469-1487.
17. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol 1999; 6: 590-595.
18. Boulanger H, Mansouri R, Gautier JF et al. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol Dial Transplant 2006; 21: 2696-2702.
19. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815.
20. Song J, Knepper MA, Hu X et al. Rosiglitazone activates renal sodium and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308: 426-433.
21. + transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia. Kidney Int 2004; 65: 175-183.
22. + transporters in kidneys of rats with ischemia-induced acute renal failure. Am J Physiol Renal Physiol 2000; 278: F925-F939.
23. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723.
24. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 1993-1995.
25. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
26. Izzedine H, Hulot JS, Vittecoq D et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-746.
27. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817.
28. Eira M, Araujo M, Seguro AC. Urinary NO3 excretion and renal failure in indinavir-treated patients. Braz J Med Biol Res 2006; 39: 1065-1070.
29. de Araújo M, Seguro AC. Vasodilator agents protect against indinavir nephrotoxicity. Antivir Ther 2003; 8: 295-299.
30. Ma LJ, Marcantoni C, Linton MF et al. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
31. Sivarajah A, Chatterjee PK, Patel NS et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003; 23: 267-276.
32. Lee S, Kim W, Moon SO et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006; 21: 2096-2105.
33. Polikandriotis JA, Mazzella LJ, Rupnow HL et al. Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
34. Kinae E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 2005; 19: 2031-2033.
35. Na KY, Oh YK, Han JS et al. Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. Am J Physiol 2003; 284: F133-F143.
36. Cirino CM, Kam VL. Hypokalemia in HIV patients on tenofovir. AIDS 2006; 209: 1671-1673.
37. Ray AS, Cihlar T, Robinson KL et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304.
38. Cox PJ, Ryan DA, Hollis AM et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772-780.
39. Guan YF, Hao C, Cha DR et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866.
40. Khan O, Riazi S, Hu X et al. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 2005; 289: 442-450.
41. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2571.
42. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003; 9: 406-416.
43. Biesecker G, Karimi S, Desjardins J. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 2003; 58: 217-225.